Complete dosing information for tezepelumab
Medical guidance required: Dosing information here is for educational purposes. Your healthcare provider will determine the appropriate dose based on your specific condition, kidney function, other medications, and medical history. Never adjust your dose without consulting your doctor or pharmacist.
The recommended dose of tezepelumab is 210 mg administered as a single subcutaneous injection once every 4 weeks (monthly). It is intended as an add-on therapy and should not replace inhaled corticosteroids or other controller medications. The injection is given in the abdomen, thigh, or upper arm. Tezspire is available as a 210 mg/1.9 mL single-dose prefilled syringe or autoinjector pen. There is no dose adjustment recommended based on weight, age, or asthma phenotype. If a dose is missed, administer as soon as possible and resume the regular monthly schedule.
Safety and efficacy have not been established in children under 12 years of age. For adolescents aged 12 to 17 years, the dose is the same as adults: 210 mg subcutaneously once every 4 weeks.
No dose adjustment is required in patients with renal impairment. Formal pharmacokinetic studies in severe renal impairment are limited; use with standard monitoring.
No dose adjustment is required in patients with hepatic impairment. Monoclonal antibodies are not primarily metabolized via hepatic CYP450 pathways.